TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04473859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered immediately after punch-biopsy and 24 hours after punch biopsy.
Study: NCT02747927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDV placebo-matching SC injection.
Study: NCT00819234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pramlintide and placebo metreleptin twice daily
Study: NCT01543685
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg TID capsules
Study: NCT01543685
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg BID capsules
Study: NCT01543685
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg TID capsules
Study: NCT01543685
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg capsules
Study: NCT01543685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT05347628
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1004 is a capsule in the form of 10mg and 40mg.
Study: NCT00004921
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01041911
Drug: Euphorbia tablets
Normalized name: Euphorbia hirta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, tablet, once daily, 14 days
Study: NCT01041911
Drug: Euphorbia tablets
Normalized name: Euphorbia hirta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, tablet, once daily, 14 days
Study: NCT01041911
Drug: Euphorbia tablets
Normalized name: Euphorbia hirta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
Study: NCT03418779
Drug: Immunosuppressants
Normalized name: IMMUNOSUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 109/L and platelets \< 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
Study: NCT01041911
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, tablet, once daily, 14 days
Study: NCT03288636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02074839
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study: NCT03579888
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01115972
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00390013
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.
Study: NCT04197440
Drug: BAM8-22 2mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study: NCT04197440
Drug: BAM8-22 1mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study: NCT04197440
Drug: BAM8-22 0.5 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study: NCT04197440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study: NCT04197440
Drug: BAM8-22 with 5 SPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
Study: NCT04197440
Drug: BAM8-22 with 25 SPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
Study: NCT04197440
Drug: BAM8-22 with inactivate cowhage spicules
Normalized name: pertussis, inactivated, whole cell, combinations with toxoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT02404142
Drug: saline isotonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ranolazine administered orally twice daily
Study: NCT03034967
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
Study: NCT03034967
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
Study: NCT00364156
Drug: Standard Patch Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-weeks of nicotine patch + 16-weeks of placebo
Study: NCT01142336
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg qHS for 1 year
Study: NCT01142336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet qHS for 1 year
Study: NCT03796351
Drug: MT10107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Study: NCT00584597
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel S 1 mL
Study: NCT00584597
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel S 2mL
Study: NCT03337503
Drug: THC and CDB in a 1 to 1 ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing cannabis oil
Study: NCT03337503
Drug: Experimental: THC and CBD in a 1 to 2 ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing cannabis oil
Study: NCT03904719
Drug: CM082 plus JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study: NCT00584597
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel S 3mL
Study: NCT04519424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride)
Study: NCT02646085
Drug: C11 Methionine positron emission tomography
Normalized name: Choline C11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
Study: NCT00690456
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT02622893
Drug: Transperitoneal laparoscopic nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
Study: NCT02622893
Drug: Retroperitoneal laparoscopic nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
Study: NCT00490308
Drug: Treatment with estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01096940
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, BID dose
Study: NCT01096940
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet, single dose
Study: NCT03649555
Drug: [18F]-FTC-146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
Study: NCT04501796
Drug: Double-Blind NT-I7
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intramuscular (IM) injection
Study: NCT04501796
Drug: Double-Blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00166530
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
Study: NCT00166530
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
Study: NCT02359435
Drug: Reverse hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
Study: NCT02359435
Drug: Standard triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
Study: NCT03160651
Drug: Methylprednisolone or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 28 days of methylprednisolone 32 mg/day
Study: NCT03402828
Drug: Any topical drug treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment strategy used to prevent relapse of psoriasis symptoms
Study: NCT00998283
Drug: HM10460A 5μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT00998283
Drug: HM10460A 15μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT00998283
Drug: HM10460A 45μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT00998283
Drug: HM10460A 135μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT00998283
Drug: HM10460A 350μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT00998283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT03931070
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
Study: NCT02850627
Drug: Tongguan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
Study: NCT02850627
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
Study: NCT02707497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will not use any platelet-increased drugs.
Study: NCT02180022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, placebo was treated for 12 weeks
Study: NCT04225221
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
Study: NCT04225221
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
Study: NCT01795027
Drug: S-1 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 courses S-1 single after d D2 resection
Study: NCT03020368
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01695343
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04311957
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
Study: NCT01093508
Drug: APD916
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04044742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving Placebo injection
Study: NCT03988387
Drug: daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
Study: NCT00988780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Study: NCT02157714
Drug: PRX002
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01406340
Drug: 5 mg GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
Study: NCT00763867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01221077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As of 01 March 2013, the matching placebo is no longer being administered
Study: NCT02371031
Drug: 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02243007
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02499770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003543
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00755755
Drug: PGL4001 (ulipristal) and iron
Normalized name: iron and multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00755755
Drug: PGL4001 (ulipristal) and iron
Normalized name: iron and multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03208556
Drug: Fludarabine and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
Study: NCT02577016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to sitagliptin administered orally
Study: NCT00691184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
Study: NCT02359058
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03210532
Drug: Telmisartan + Amlodipine + Rosuvastatin
Normalized name: amlodipine / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
Study: NCT03210532
Drug: Telmisartan + Rosuvastatin
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
Study: NCT00678457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01101919
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
Study: NCT00542022
Drug: MK0812 / Duration of Treatment: 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02347917
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg orally twice daily (960 mg total daily dose)
Study: NCT01414166
Drug: ERN/LRPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
Study: NCT01389765
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01414166
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
Study: NCT01288430
Drug: DS-2248
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
Study: NCT03708146
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Study: NCT03708146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Study: NCT03461042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily before bedtime for 12 weeks since informed consent
Study: NCT03772223
Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
Study: NCT03772223
Drug: Treatment C (Albuterol Sulfate metered dose inhaler)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Study: NCT00002784
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.